secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2023-06-27T23:59:59+00:00
Accession:  0001437749-23-018626
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex provides clinical updates: Acclaim-1 Phase 2 expansion approved, patient dosing delayed to Q3 2023
--------------------------------------------------------------------------------

- Acclaim-1 Phase 1 completed; SRC approved Phase 2 expansion at 0.12 mg/kg; first patient expected Q3 2023.
- Acclaim-2 enrollment slower than anticipated; Phase 1 dose escalation completion expected Q1 2024.
- Acclaim-3 protocol filed Nov 2022; first patient expected Q3 2023; delays due to LNP CDMO transition.
- Company has enough REQORSA supply through Sep 2023; plans to produce more but trials would be delayed if not.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/0001437749-23-018626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923018626/gnpx20230615_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-018626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer